Berenberg

  • Land: Deutschland

Nachricht vom 17.05.2018 | 17:40

RMM SA sells up to 3.91% of Biocartis Group NV's outstanding shares

DGAP-News: Joh. Berenberg, Gossler & Co. KG / Key word(s): Miscellaneous

17.05.2018 / 17:40
The issuer is solely responsible for the content of this announcement.


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

PRESS RELEASE 17 May 2018


 

RMM SA sells up to 3.91% of Biocartis Group NV's outstanding shares

RMM SA, an investment company, currently holding 7.77% of the outstanding shares in Biocartis Group NV ("Biocartis"), today announces that it will sell up to approx. 50% (up to 2,000,000 shares) of its stake in an accelerated bookbuilding process to international institutional investors only. This represents up to 3.91% of Biocartis issued share capital.

RMM SA agreed to a lock-up of 90 days (subject to customary exemptions) for its remaining shares. The placement will start immediately and is expected to be completed later today. RMM SA is connected with Rudi Mariën, former director of Biocartis.

Joh. Berenberg, Gossler & Co. KG will be acting as Sole Bookrunner in the Transaction. The Transaction is subject to certain customary conditions precedent.

The information was submitted for publication at 17:40 CEST on 17 May 2018 by RMM SA.


 

Disclaimer / Important Note

This publication may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions), Australia, Canada, Japan or South Africa or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This publication does not constitute an offer of securities for sale or a solicitation of an offer to purchase the above mentioned securities in the United States, Germany or any other jurisdiction.

Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. The securities of Biocartis may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The securities of the Biocartis have not been, and will not be, registered under the Securities Act. There will be no public offering of the securities in the United States. Any sale in the United States of the Securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in, and in reliance on, Rule 144A or another exemption under the Securities Act.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In member states of the European Economic Area ("EEA") which have implemented the Prospectus Directive (each, a "Relevant Member State"), this announcement and any offer if made subsequently is directed exclusively at persons who are "qualified investors" within the meaning of the Prospectus Directive ("Qualified Investors"). For these purposes, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto to the extent implemented in a Relevant Member State), and includes any relevant implementing measure in the Relevant Member State. No action has been taken that would permit an offering of the securities or possession or distribution of this announcement in any jurisdiction where action for that purpose is required.

Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.



17.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

GBC-Fokusbox

BIG Blockchain Intelligence Group: Coverage Initiated mit Kaufen-Rating

BIG Blockchain Intelligence Group Inc. bietet Software-Lösungen an, die eine Echtzeitüberprüfung von blockchainbasierten Transaktionen mit Hilfe von Such- und Analysefunktionen ermöglicht. Zur Kernkompetenz gehört eine Software, die zur Generierung von Daten aus Blockchain-Transaktionen verwendet wird. Aktuell konzentriert sich BIG auf Transaktionen von Kryptowährungen und bedient seine Kunden wie Regierungen, Strafverfolgungsbehörden, Banken und Finanzdienstleistern oder E-Commerce-Anbieter mit entsprechender Sicherheitstechnologie. Bei einem Kursziel von 1,03 CAD (0,69 €) lautet das Rating KAUFEN.

News im Fokus

Beiersdorf Aktiengesellschaft: Aufsichtsrat ernennt Stefan De Loecker zum Vorstandsvorsitzenden von Beiersdorf

15. Oktober 2018, 12:30

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

15. Oktober 2018